Novartis has secured a second approval for Kymriah (tisagenlecleucel) in the US for the treatment of adult patients with relapsed or refractory (r/r) large B-cell lymphoma who had more than two lines of systemic therapy. […]
Merck said that the US Food and Drug Administration (FDA) has accepted for review a supplemental Biologics License Application (sBLA) for its anti-PD-1 therapy Keytruda based on the results of the phase 3 KEYNOTE-189 trial. […]
The UK National Institute for Health and Care Excellence (NICE) has recommended the use of Keytruda (pembrolizumab) within the Cancer Drugs Fund for the treatment of bladder cancer. Keytruda has been recommended as an option […]
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion on the company’s Marketing Authorization Application (MAA) for HIV-1 drug candidate Biktarvy. Biktarvy is a combination of […]
Research carried out by Imperial College London has showed that small alterations to existing diabetes treatments can increase their effectiveness by changing their interactions with cells. Researchers tested a modified version of a type 2 […]